{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:05:05Z","timestamp":1784909105925,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ymgmr.2026.101318","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:45:09Z","timestamp":1778820309000},"page":"101318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of migalastat therapy on corneal deposits in a female with Fabry disease: A case report"],"prefix":"10.1016","volume":"47","author":[{"given":"Nicola","family":"Vitturi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Gugelmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Zanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Lenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ymgmr.2026.101318_bb0005","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"issue":"5","key":"10.1016\/j.ymgmr.2026.101318_bb0010","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/bjophthalmol-2019-314249","article-title":"Cornea verticillata in Fabry disease: a comparative study between slit-lamp examination and in vivo corneal confocal microscopy","volume":"104","author":"Leonardi","year":"2020","journal-title":"Br. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.ymgmr.2026.101318_bb0015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ymgmr.2026.101318_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123726","article-title":"Mutations in the GLA gene and LysoGb3: Is it really Anderson-Fabry disease?","volume":"19","author":"Duro","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ymgmr.2026.101318_bb0025","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/bjo.2006.100602","article-title":"Ocular manifestations of Fabry\u2019s disease: data from the Fabry outcome Survey","volume":"91","author":"Sodi","year":"2007","journal-title":"Br. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.ymgmr.2026.101318_bb0030","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet. J. Rare Dis."},{"issue":"6","key":"10.1016\/j.ymgmr.2026.101318_bb0035","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.amjms.2020.07.011","article-title":"When and how to diagnose Fabry disease in clinical Pratice","volume":"360","author":"Michaud","year":"2020","journal-title":"Am. J. Med. Sci."},{"issue":"4","key":"10.1016\/j.ymgmr.2026.101318_bb0045","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet. Metab."},{"key":"10.1016\/j.ymgmr.2026.101318_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2020.08.012","article-title":"In vitro and in vivo amenability to Migalastat in Fabry disease","volume":"19","author":"Lenders","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"5","key":"10.1016\/j.ymgmr.2026.101318_bb0055","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.1321","article-title":"Oral chaperone therapy Migalastat for treating Fabry disease: Enzymatic response and serum biomarker changes after 1 year","volume":"105","author":"M\u00fcntze","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.ymgmr.2026.101318_bb0060","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1136\/bjophthalmol-2019-314906","article-title":"Fabry keratopathy: manifestations and changes over time","volume":"104","author":"Sivley","year":"2020","journal-title":"Br. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.ymgmr.2026.101318_bb0065","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/aos.12588","article-title":"Ophthalmic experience over 10 years in an observational nationwide Danish cohort of Fabry patients with access to enzyme replacement","volume":"93","author":"Fledelius","year":"2015","journal-title":"Acta Ophthalmol."},{"issue":"3","key":"10.1016\/j.ymgmr.2026.101318_bb0070","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","article-title":"Treatment of Fabry disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)","volume":"8","author":"Lenders","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"5","key":"10.1016\/j.ymgmr.2026.101318_bb0075","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"Migalastat: a review in Fabry disease","volume":"79","author":"McCafferty","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ymgmr.2026.101318_bb0080","first-page":"1","article-title":"Long-term efficacy of Migalastat in females with Fabry disease","volume":"0","author":"Kallish","year":"2025","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgmr.2026.101318_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12771","article-title":"Renal and multisystem effectiveness of 3.9 years of Migalastat in a global real-world cohort: Results from the followME Fabry pathfinders registry","volume":"48","author":"Hughes","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"issue":"22","key":"10.1016\/j.ymgmr.2026.101318_bb0090","doi-asserted-by":"crossref","first-page":"6981","DOI":"10.3390\/jcm13226981","article-title":"The unmet needs of lysosomal storage disorders from early diagnosis to caregiving pathways: An Italian perspective","volume":"13","author":"Castaman","year":"2024","journal-title":"J. Clin. Med."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426926000303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426926000303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:18:10Z","timestamp":1784906290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426926000303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":17,"alternative-id":["S2214426926000303"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2026.101318","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of migalastat therapy on corneal deposits in a female with Fabry disease: A case report","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2026.101318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101318"}}